More Than Skin Deep: Improved Strategies for Pemphigus Vulgaris Management

More Than Skin Deep: Improved Strategies for Pemphigus Vulgaris Management 

Release Date: July 15, 2020
Last Reviewed: June 7, 2020 
Expiration Date: July 15, 2021
Time to Complete Activity:  1.0 hour

*This activity expired for credit on July 15, 2021 and is no longer available for credit

Annette Czernik, MD

Associate Professor of Dermatology
Clinical Director, Mount Siani Dermatology Faculty Practice 
Icahn School of Medicine at Mount Sinai
New York, NY

Saakshi Khatri, MBBS, MD
Assistant Professor of Dermatology and Rheumatology
(Internal Medicine)
Icahn School of Medicine at Mount Sinai
Director, Center for Connective Tissue Disease
Mount Siani Health System
New York, NY

This activity is provided by Paradigm Medical Communications, LLC.   

Target Audience
This initiative has been designed to meet the educational needs of clinicians who treat patients with pemphigus vulgaris (PV), including dermatologists and rheumatologists. It may also benefit other clinicians who care for patients with PV.

Statement of Need
PV belongs to a group of rare autoimmune mucocutaneous blistering disorders that were often fatal prior to the introduction of effective treatments. High morbidity associated with side effects of corticosteroid therapy drove the search for alternate therapies with a better safety profile. Rituximab has demonstrated significantly better efficacy for induction therapy in PV, as well as efficacy for maintenance therapy and for relapsed disease. Studies have shown greater benefit with earlier rituximab therapy, yet adoption of rituximab therapy has been slow despite its proven benefits. A lack of updated guidelines that include evidence-based recommendations for rituximab induction, along with heterogenous disease presentation and other challenges, leave clinicians in need of education about optimal management of PV. Education targeting dermatologists, who most frequently diagnose PV, and rheumatologists, who have experience using rituximab, can foster better understanding and preparedness to effectively treat this disease.

Learning Objectives
Upon proper completion of this activity, participants should be better able to:

  • Develop evidence-based initial treatment strategies for patients with systemic PV 
  • Select appropriate maintenance therapies for PV based on clinical evidence and patient characteristics
  • Determine effective therapy for patients who have relapsed or refractory PV 

Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points [and patient safety MOC credit] in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

This activity is supported by an educational grant from Genentech. 

Instructions for Participation 
To receive a CME certificate of participation, you should:

  • Follow instructions to register or log in with your professional information and complete the preactivity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation. 

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. 
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: 

Technical Support: If you have any technical problems or playback issues, email us at

In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Annette Czernik, MD
Has no financial relationship to disclose 

Saakshi Khatri, MBBS, MD
Consulting Fees: Novartis, Pfizer Inc.
Speakers Bureau: Pfizer Inc.

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer and patient reviewers have no financial relationships to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at

© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.